Articles From: AirAsia Flight 8501 Fuselage Found to Ultragenyx Initiates New Development Program Studying KRN23 for the Treatment of Tumor-Induced Osteomalacia


2015/1/14
By Ben Otto in Jakarta and Richard C.
Sign-up for AirAsia Flight 8501 Fuselage Found investment picks
2015/1/14
By Ben Otto in Jakarta and Richard C.
Sign-up for AirAsia Flight 8501 Fuselage Found investment picks
2015/1/4
By Ben Otto in Jakarta and Richard C.
Sign-up for AirAsia Flight 8501 Search Finds Fifth Large Object -- Update investment picks
2015/1/7
By Ben Otto in Jakarta and Richard C.
Sign-up for Indonesia Finds Tail of AirAsia Plane -- 3rd Update investment picks
2015/1/7
By Ben Otto in Jakarta and Richard C.
Sign-up for Indonesia Finds Tail of AirAsia Plane -- 2nd Update investment picks
2015/1/4
By Ben Otto in Jakarta and Richard C.
Sign-up for AirAsia Flight 8501 Search Finds Fifth Large Object -- 2nd Update investment picks
2015/1/4
By Ben Otto in Jakarta and Richard C.
Sign-up for Search for AirAsia Flight 8501 Finds Fifth Large Object investment picks
2015/1/7
By Ben Otto JAKARTA, Indonesia--Indonesia has located the tail of AirAsia Flight 8501 in the Java Sea, the country's search-and-rescue agency said Wednesday.
Sign-up for Indonesia Finds Tail of AirAsia Plane--Update investment picks
2015/1/13
By Ben Otto JAKARTA, Indonesia--In an unassuming, two-room lab near a cluster of government offices here, the National Transportation Safety Committee is preparing to piece together the final moments of AirAsia Flight 8501.
Sign-up for AirAsia Crash: Indonesia Lab Ready to Look at Flight 8501's Final Moments investment picks
2014/12/30
By Ben Otto JAKARTA, Indonesia--Indonesia has recovered at least six bodies from waters around what is believed to be the crash site of an AirAsia jet, a Navy admiral told a local television station Tuesday.
Sign-up for Indonesia Recovers at Least Six Bodies in Search for AirAsia Jet, Navy Admiral Says investment picks
2015/1/17
By Ben Otto JAKARTA, Indonesia--Divers failed for a third day to reach the fuselage of AirAsia Flight 8501, thwarted by Saturday's strong currents in the Java Sea.
Sign-up for AirAsia Flight 8501: Strong Currents Hamper Efforts to Reach Fuselage investment picks
2015/1/3
By Ben Otto JAKARTA--Indonesia has discovered four larges pieces of AirAsia Flight 8501 on the floor of the Java Sea and stands ready to deploy detectors to locate the jet's all-important black boxes, the head of the country's search-and-rescue agency said Saturday evening.
Sign-up for Four Large Parts of AirAsia Plane Found - Indonesia SAR Chief investment picks
2014/10/27
http://media.marketwire.com/attachments/201404/237738_237722_JLLLogoFinalArtwork_RGB.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1153929&ProfileId=051205&sourceType=1 CHICAGO, IL --
Sign-up for Corporations Find Surprising Path to Business Productivity Through Real Estate Data investment picks
2015/1/20
By Benoît Faucon TEHRAN--As talks over lifting sanctions on Iran drag on, Renault SA is positioning itself for what executives hope will be a reopening of one of the Middle East's biggest car markets.
Sign-up for Renault Gearing Up in Case Iran Auto Market Reopens investment picks
2014/11/7
By Beth Baker First there were in-law apartments.
Sign-up for UPDATE: A backyard cottage for Mom and Dad investment picks
2015/1/3
By Beth Reinhard Former Arkansas Gov.
Sign-up for Huckabee to Mull a Presidential Run -- Update investment picks
2015/1/3
By Beth Reinhard Former Arkansas Gov.
Sign-up for Hucakbee to Mull Another Presidential Bid investment picks
Supports Hybrid deployment and localized data trends ARMONK, N.Y. , Dec.
Sign-up for IBM Adds Cloud Centers in Europe, Asia and the Americas investment picks
Marcus Theatres ® , a division of The Marcus Corporation (NYSE:MCS), is continuing its multi-million dollar investment in its circuit to bring consumers the ultimate movie-going experience.
Sign-up for Marcus Theatres® Continues to Invest in Creating the Ultimate Movie-Going Experience investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) in patients with ipilimumab-refractory advanced melanoma (n=540). At six months, the PFS rates for KEYTRUDA were 34 percent at the 2 mg/kg dose (95% CI, 27-41) (n=180) and 38 percent at the 10 mg/kg dose (95% CI, 31-45) (n=181), compared to 16 percent for chemotherapy (95% CI, 10-22) (n=179). The median duration of follow-up at the interim analysis was 10 months.
Sign-up for Merck Announces Positive Study Investigating the Use of KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA ® (pembrolizumab) – the company’s anti-PD-1 therapy – in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). These studies will be presented in oral sessions at the Society for Melanoma Research (SMR) 2014 International Congress, Nov.
Sign-up for New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA ® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma Kinase (ALK) rearrangement-negative non-small cell lung cancer (NSCLC) whose disease has progressed on or following platinum-based chemotherapy.
Sign-up for Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer investment picks
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall response rate of 18.5 percent with KEYTRUDA, the company’s anti-PD-1 therapy, as assessed by RECIST v1.1, central review (n=5/27), in PD-L1 positive, advanced triple-negative breast cancer – one of the most aggressive forms of breast cancer.
Sign-up for Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA ® (pembrolizumab), the company’s anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin.
Sign-up for Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting investment picks
The International Breast Cancer Study Group (IBCSG), Breast International Group (BIG), and Merck, known as MSD outside the United States and Canada, today announced the opening of the PANACEA study, a global collaborative study exploring a new way to treat HER2+ breast cancer that has become resistant to the current standard of care.
Sign-up for International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer investment picks
Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly and Company (NYSE:LLY) announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: The agreement is between Lilly and Merck, through a subsidiary.
Sign-up for Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer investment picks
LEHIGH VALLEY, Pa.
Sign-up for Air Products Introduces Portable Shielding Gas Blending System at FABTECH investment picks
2014/11/18
Latest PIC32MX1/2/5 Series Enables a Wide Range of Applications, Including Digital Audio, Bluetooth®, Industrial Connectivity, USB and General-Purpose Embedded Control at Lower Prices CHANDLER, Ariz.
Sign-up for Microchip Introduces New Low Cost PIC32MX1/2/5 32-bit Microcontroller Series With Feature-Rich Peripheral Mix and Large, Scalable Memory Configuration investment picks
2014/12/18
AB Value Management LLC, an investment management company that owns greater than 11% of Kreisler Manufacturing Corporation's (OTC Pink: KRSL) common stock announces the following: Kreisler Manufacturing Corporation (the “Company”) failed to achieve a quorum at its December 18, 2014 scheduled annual meeting.
Sign-up for AB Value Management LLC Announces Continued Action to Seek Election of Its Directors to the Board of Kreisler Manufacturing Corp. investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: AirAsia Flight 8501 Fuselage Found to Ultragenyx Initiates New Development Program Studying KRN23 for the Treatment of Tumor-Induced Osteomalacia
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent